Transgene SA (TNG.PA)

Paris - Paris Delayed Price. Currency in EUR

1.0040

-0.0380

(-3.65%)

At close: 05:35PM CEST

All

Clinical Trials Arena
Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint
Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.
GlobeNewswire
Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
Top line data show that the randomized Phase II study of TG4001 in combination with avelumab versus avelumab alone in patients with recurrent or metastatic HPV16-positive cervical and anogenital tumors did not meet the primary objective of improvement in progression-free survival Pre-planned subgroup analysis showed a positive efficacy trend in favor of the TG4001 containing regimen in patients with cervical cancer Transgene will complete full analysis of the data before deciding on the best way